Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
pCR bij gereseceerd pancreasadenocarcinoom na preoperatieve chemo(radio)therapie
sep 2024 | Maag-darm-leveroncologie